Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 5/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13217925 | 1.00 | TSPO (0.66) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217935 | 0.95 | TSPO (0.65) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3022530 | 0.95 | TSPO (0.65) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3030876 | 0.94 | TSPO (0.64) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217938 | 0.94 | TSPO (0.64) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3030326 | 0.94 | TSPO (0.68) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3035751 | 0.93 | TSPO (0.78) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217932 | 0.93 | TSPO (0.78) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3024469 | 0.93 | TSPO (0.66) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3034122 | 0.92 | TSPO (0.71) | TSPONR1I2ABCB11ALBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752415-B1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECH ORGANISATION (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-2752415-B1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECH ORGANISATION (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-2752415-A1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2014-07-09 | — | — | EP | disclosed |
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION | 2010-08-19 | — | — | US | disclosed |
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | GABRA6, GABRA1, GABRA2 | TSPO 41/4885NR1I2 38/4885ABCB11 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.